单倍群
优势比
肾脏疾病
内科学
人线粒体DNA单倍型
置信区间
等位基因
肾功能
生物
医学
单核苷酸多态性
单倍型
基因型
胃肠病学
遗传学
基因
作者
Jianghong Guo,Jianming Shi,Guo‐Ping Shi,Yong Wang,Xue‐Feng Chu,Zhengdong Wang,Shun Yao,Xuehui Sun,Xiaofeng Wang,Yin‐Sheng Zhu,Xiaoyan Jiang
出处
期刊:Genetic Testing and Molecular Biomarkers
[Mary Ann Liebert]
日期:2021-08-01
卷期号:25 (8): 546-550
被引量:3
标识
DOI:10.1089/gtmb.2020.0306
摘要
Objective: To explore the associations of common mitochondrial DNA polymorphisms with chronic kidney disease (CKD). Methods: Data from 286 longevous individuals aged 95 years or older from the longevity arm from the Rugao Longevity and Ageing Study (RuLAS) were used. Twenty-eight common haplogroups defined by 33 single nucleotide polymorphisms were genotyped using SNaPshot minisequencing reaction assays. The creatinine-based estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Results: The prevalence of CKD was 23.6% among the longevous participants aged 95 years and older. The D haplogroup (67.37 ± 14.72 vs. 70.65 ± 11.07, p = 0.045), the D5 haplogroup (60.86 ± 18.36 vs. 70.34 ± 11.53, p = 0.002), and the 5178A allele (67.23 ± 14.48 vs. 70.75 ± 11.10, p = 0.029) were associated with lower eGFR levels compared with noncarriers. The D5 haplogroup (13.8% vs. 3.6%, p = 0.005) was significantly higher, while D haplogroup (35.4% vs. 24%, p = 0.067) and the 5178A allele (36.9% vs. 24.9%, p = 0.056) were borderline significantly higher in CKD individuals than those without CKD. Further, after adjusting for multiple covariates, the D haplogroup, the D5 haplogroup, and the 5178A allele were associated with increased odds of CKD with odds ratios of 1.93 (95% confidence interval [CI]: 1.00-3.72, p = 0.050), 4.76 (95% CI: 1.49-15.22, p = 0.009) and 2.04 (95% CI: 1.05-3.96, p = 0.035), respectively. Conclusions: The D and D5 haplogroups, as well as the 5178A allele are associated with decreased eGFR levels and an increased risk of CKD in a longevous population.
科研通智能强力驱动
Strongly Powered by AbleSci AI